PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Sildenafil - Raynaud's Phenomenon

PAD Profile : Sildenafil - Raynaud's Phenomenon

Keywords :
digital ulceration, Raynaud's disease, Raynaud's syndrome, systemic sclerosis

Traffic Light Status

Status 1 of 1.

Status :
Blue
Important
Formulations :
  • Tablets
Important Information :
Transfer of prescribing to primary care only after specialist team initiation and supply of at least the first month of treatment.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Un
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
02 December 2020
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands ICS Area Prescribing Committee approves sildenafil (generic – off label use) for the treatment of Raynauds Phenomenon (RP) secondary to systemic sclerosis, in patients with or without digital ulceration.

Sildenafil will be given a BLUE (with information sheet) traffic light status.

Please see the BLUE information sheet (agreed in April 2021) below for further information.

Associated BNF Codes

02. Cardiovascular System
02.05.01. Vasodilator antihypertensive drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More